• Information for Healthcare Professionals (PDF)
• Reimbursement
• Resources
• Safety Information

VELCADE^® (bortezomib) for Injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

For further information about VELCADE and Mantle Cell Lymphoma (MCL), select a menu item in the list to the left.

Please CLICK HERE to view important safety information.

For full Prescribing Information CLICK HERE. (PDF)

For further information about VELCADE^® (bortezomib) for Injection,
call 1-866-VELCADE (U.S. clinicians only).